emerg
synthet
biolog
hold
great
hope
provid
solut
unmet
need
humankind
review
articl
describ
synthet
biolog
deliv
promis
field
drug
discoveri
provid
novel
opportun
throughout
entir
drug
discoveri
process
synthet
biolog
tool
enabl
diseas
mechan
target
identif
elucid
also
provid
avenu
discov
small
chemotherapeut
molecul
design
novel
biopharmaceut
furthermor
synthet
biologist
design
costeffect
microbi
product
process
complex
natur
product
could
help
overcom
global
drug
shortag
impress
advanc
achiev
year
indic
potenti
synthet
biolog
correspond
author
fussenegg
fussenegg
bsseethzch
wwwdrugdiscoverytodaycom
took
almost
centuri
synthet
biolog
first
introduc
research
biolog
suffici
character
fundament
biolog
process
use
design
construct
new
biolog
part
devic
system
redesign
exist
natur
biolog
system
http
syntheticbiologyorg
sinc
pioneer
work
synthet
biolog
led
construct
live
system
display
complex
dynam
behavior
synthet
epigenet
imprint
timedelay
function
oscil
express
pattern
well
synthet
ecosystem
emul
coexist
differ
speci
habitat
review
see
along
fundament
synthet
biolog
whose
aim
elucid
establish
design
principl
biolog
part
devic
system
translat
synthet
biolog
may
provid
solut
pertin
challeng
biotechnolog
agricultur
environment
scienc
detail
analysi
enzym
transcript
factor
receptor
provid
collect
function
dynam
inform
individu
biobrick
process
mathemat
model
offer
precis
clue
rapid
success
assembl
complex
synthet
biolog
devic
live
system
speed
ration
design
implement
synthet
devic
significantli
increas
recent
year
combin
advanc
gene
synthesi
technolog
provid
larg
custommad
dna
sequenc
moder
cost
within
shorter
timelin
ii
viral
nonvir
genetransf
technolog
enabl
straightforward
instal
transgen
differ
target
cell
iii
modelbas
evalu
genet
assembl
identifi
crucial
design
paramet
simul
devic
dynam
experiment
implement
progress
hold
promis
streamlin
intensifi
drug
discoveri
process
chain
exemplifi
studi
highlight
review
articl
target
identif
facilit
synthet
reconstruct
signal
pathway
enabl
identif
diseasecaus
element
target
identifi
whole
cell
screen
assay
design
use
synthet
biolog
strategi
allow
streamlin
integr
drug
discoveri
process
beyond
discoveri
smallmoleculebas
therapeut
synthet
biolog
provid
novel
opportun
design
biolog
exampl
construct
bacteriophag
superior
antiinfect
properti
synthet
biolog
use
produc
complex
plantderiv
natur
compound
microbi
host
therebi
provid
econom
manufactur
process
synthet
biolog
understand
molecular
basi
diseas
wherea
classic
hypothesisdriven
basic
research
disciplin
take
nativ
biolog
system
apart
understand
function
synthet
biolog
focus
assembl
artifici
devic
wellestablish
natur
engin
compon
unravel
biolog
phenomena
scienc
base
statement
richard
feynman
creat
understand
exemplari
studi
b
cell
antigen
receptor
bcr
signal
process
synthet
reconstruct
drosophila
schneider
cell
could
studi
interferencefre
cellular
environ
evolutionari
distanc
insect
mammal
cell
easili
transfect
mani
differ
vector
enabl
reconstruct
multistep
signal
pathway
isol
investig
signal
compon
permit
novel
insight
signal
network
topolog
reveal
posit
feedback
loop
result
strong
amplif
bcr
signal
alloster
tyrosin
kinas
syk
bind
activ
phosphoryl
bcr
immunoreceptor
tyrosinebas
activ
motif
itam
activ
syk
phosphoryl
neighbor
itam
result
bind
activ
syk
posit
feedback
loop
therebi
trigger
rapid
amplif
bcr
signal
followup
studi
group
appli
synthet
reconstruct
bcr
signal
cell
elucid
molecular
basi
rare
form
agammaglobulinemia
primari
immunodefici
character
earli
block
b
cell
develop
induc
express
igm
bcr
complex
constitu
cell
reveal
nonsens
mutat
igb
prevent
correct
associ
iga
therebi
inhibit
function
bcr
format
studi
describ
highlight
synthet
reconstruct
natur
signal
event
orthogon
host
elucid
physiolog
patholog
network
topolog
understand
genet
underpin
inherit
diseas
recent
studi
synthet
reconstruct
sever
acquir
respiratori
syndrom
sar
coronavirus
reveal
zoonot
virus
acquir
human
tropism
bioinformat
analysi
suggest
sar
epidem
begin
centuri
origin
bat
coronaviru
cross
barrier
zoonot
human
tropism
understand
evolutionari
strategi
jump
speci
barrier
would
provid
clue
futur
epidem
sar
virus
might
look
like
lay
basi
design
prevent
therapeut
vaccin
investig
natur
zoonot
viru
reservoir
bat
hamper
fact
possibl
propag
bat
coronavirus
cell
cultur
laboratori
anim
therefor
becker
et
al
exchang
ectodomain
spike
type
membran
glycoprotein
bat
coronaviru
synthet
construct
harbor
mutat
found
sar
coronavirus
synthet
virus
replic
murin
primat
cell
well
infect
mice
demonstr
insert
synthet
spike
protein
effici
promot
crossspeci
shift
tropism
moreov
demonstr
chimer
virus
abl
bind
human
angiotensinconvert
enzym
receptor
requir
cell
entri
synthet
infecti
sequenc
might
help
predict
directli
test
pathway
could
assist
rapidli
recov
test
newli
identifi
pathogen
henc
adapt
intervent
strategi
futur
epidem
similar
approach
reconstruct
sar
coronavirus
sequenc
spanish
influenza
pandem
viru
enabl
synthet
reconstruct
eight
gene
segment
pandem
viru
fuse
noncod
gene
sequenc
close
relat
viru
contrast
contemporari
influenza
virus
reconstruct
viru
abl
replic
absenc
trypsin
lethal
mice
embryon
chicken
egg
show
high
growth
phenotyp
human
bronchial
epitheli
cell
correl
deadli
properti
mutat
observ
influenza
gene
sequenc
might
help
understand
evolut
viru
well
character
virul
factor
ultim
design
prevent
vaccin
possibl
strategi
design
vaccin
reconstruct
virus
recent
implement
use
polioviru
variant
engin
differenti
codon
usag
shown
unfavor
codon
result
viru
attenu
virul
could
use
immun
mice
provid
protect
immun
challeng
given
high
number
unfavor
alter
codon
attenu
virus
unlik
revert
natur
virul
strain
might
therefor
repres
safe
approach
design
human
vaccin
avail
wellcharacter
standard
biolog
part
repressordna
interact
transactiv
domain
minim
promot
report
system
enabl
assembl
design
circuit
mimic
pathway
essenti
human
pathogen
involv
major
patholog
could
use
screen
interf
smallmolecul
drug
use
transgen
host
cell
recent
synthet
biolog
studi
use
engin
mammalian
cell
small
molecul
discov
switch
resist
mycobacteria
antibiot
ethionamid
fig
mycobacterium
tuberculosi
inher
resist
ethionamid
must
first
activ
tuberculosi
baeyervillig
monooxygenas
etha
howev
activ
tend
ineffici
etha
product
repress
transcript
level
tetrcamrtyp
repressor
ethr
therefor
inactiv
ethr
expect
correl
increas
etha
express
higher
sensit
pathogen
ethionamid
attempt
screen
compound
inactiv
ethr
toxic
mammalian
cell
penetr
mammalian
cell
membran
reach
intracellular
pathogen
ethrbas
synthet
genet
circuit
design
engin
human
embryon
kidney
cell
fig
chimer
transcript
factor
construct
compris
ethr
fuse
transactiv
bind
ethrspecif
oper
ethr
trigger
activ
downstream
minim
promot
result
express
report
gene
seap
human
placent
secret
alkalin
phosphatas
configur
use
screen
chemic
librari
reveal
sever
compound
inhibit
ethr
follow
viabil
screen
cell
line
compromis
smallmolecul
ester
met
criteria
activ
etha
express
tuberculosi
render
pathogen
sensit
antibiot
ethionamid
therebi
provid
novel
therapeut
option
treatment
tuberculosi
variant
screen
technolog
describ
aubel
et
al
streptomyc
pristinaespiralisderiv
streptograminrespons
repressor
pip
engin
mammalian
cell
repress
piprespons
promot
control
transcript
report
gene
addit
streptogramin
antibiot
prinstinamycin
releas
pip
promot
therebi
derepress
report
activ
system
use
screen
metabol
librari
streptomyc
identifi
bacteri
strain
produc
compound
activ
clinic
pathogen
abl
penetr
mammalian
cell
show
toxic
side
effect
mammalian
cell
physiolog
similar
approach
might
feasibl
use
antibioticrespons
repressor
protein
function
transfer
mammalian
cell
macrolidespecif
mphr
tetracyclinespecif
tetr
key
characterist
anticanc
drug
select
kill
divid
cell
affect
mitot
inact
cell
recent
describ
synthet
gene
network
emul
emerg
prolifer
cancer
cell
nondivid
cell
popul
chines
hamster
ovari
cell
engin
tetracyclinetrigg
gene
network
control
express
cyclinedepend
kinas
inhibitor
presenc
tetracyclin
tetracyclinedepend
transactiv
tta
inact
express
silent
howev
upon
tetracyclin
withdraw
tta
bind
cognat
promot
p
tet
drive
transcript
cyclinedepend
kinas
inhibitor
trigger
growth
arrest
howev
condit
sustain
prolifer
control
individu
cell
emerg
precis
frequenc
escap
arrest
resum
growth
situat
proliferationcompet
cell
appear
within
growtharrest
termin
differenti
tissu
popul
reminisc
develop
cancer
mix
popul
grow
growtharrest
cell
subject
differ
clinic
licens
cancer
therapeut
follow
score
number
grow
growtharrest
cell
could
shown
cancer
therapeut
includ
doxorubicin
etoposid
select
kill
grow
cell
affect
popul
valid
growtharrest
engin
cell
cancer
model
suitabl
identifi
novel
compound
select
kill
neoplast
cell
recent
studi
stephanopoulo
cowork
analyz
sequenc
natur
antimicrobi
peptid
treat
amino
acid
sequenc
formal
languag
whose
set
regular
grammar
use
design
new
unnatur
antimicrobi
peptid
show
bacteriostat
activ
sever
speci
bacteria
includ
staphylococcu
aureu
bacillu
anthraci
new
antimicrobi
peptid
conform
formal
syntax
natur
one
popul
previous
unexplor
region
sequenc
space
antimicrobi
peptid
potenti
use
combat
bacteri
infect
suggest
less
suscept
bacteri
resist
compar
tradit
antibiot
agent
screen
compound
revers
mycobacteri
resist
antibiot
ethionamid
mycobacterium
tuberculosi
ethionamid
convert
cytotox
inhainhibit
compound
baeyervillig
monooxygenas
etha
howev
convers
tend
ineffici
etha
repress
ethr
screen
antituberculosi
compound
perform
fuse
ethr
transactiv
activ
minim
promot
p
min
upon
bind
oper
ethr
screen
librari
compound
use
cell
line
noncytotox
cellperm
ethrspecif
molecul
specif
inhibit
seap
product
besid
serv
target
discoveri
smallmolecul
drug
design
circuit
synthet
devic
could
directli
use
therapeut
compound
tailor
treat
particular
diseas
two
pioneer
studi
jim
collin
group
recent
use
synthet
biolog
approach
engin
bacteriophag
achiev
superior
antibacteri
activ
first
address
erad
biofilm
crucial
pathogenesi
clinic
import
infect
biofilm
difficult
combat
resist
antibiot
treatment
remov
host
immun
system
dissolv
biofilm
bacteriophag
engin
express
actinobacillu
actinomycetemcomitansderiv
dispersin
b
dspb
hydrolyz
crucial
extracellular
polymer
substanc
ep
need
biofilm
format
integr
staphylococcu
escherichia
coli
administr
engin
bacteriophag
e
coli
biofilm
result
initi
infect
cell
intracellular
progeni
phage
dspb
product
subsequ
releas
compound
cell
lysi
releas
dspb
loosen
biofilm
structur
degrad
ep
releas
phage
attack
neighbor
cell
therebi
reiniti
antibacteri
cycl
shown
applic
dspbengin
phage
reduc
bacteri
biofilm
cell
count
order
magnitud
order
magnitud
higher
wildtyp
control
phage
indic
engin
phage
might
becom
viabl
option
biofilm
control
environment
industri
clinic
set
asid
biofilm
format
increas
resist
antibiot
major
concern
combat
bacteri
infect
previou
effort
focus
elimin
drug
resist
use
small
molecul
inhibit
determin
resist
lu
collin
pioneer
engin
bacteriophag
target
antibiot
resist
mechan
e
coli
construct
phage
engin
product
repressor
so
respons
system
upon
so
inhibit
bacteria
suscept
antibiot
less
prone
develop
resist
antibiot
coadministr
phage
antibiot
ofloxacin
result
reduct
viabl
bacteria
order
magnitud
compar
unmodifi
phage
demonstr
express
act
synergi
blactam
aminoglycosid
antibiot
kill
bacteria
increas
surviv
e
coliinfect
mice
approach
use
engin
phage
genet
suppress
antibiot
resist
open
avenu
simultan
attack
multipl
antibacteri
target
easili
address
use
tradit
drug
compound
infect
e
coli
phage
simultan
express
csra
global
regul
energi
metabol
repressor
biofilm
format
ompf
porin
use
quinolon
enter
bacteria
result
synergist
kill
bacteria
coadminist
quinolon
ofloxacin
enhanc
bacteri
kill
synthet
biologybas
phage
could
potenti
combin
find
previou
studi
prolong
halflif
phage
mammal
avoid
clearanc
immun
system
would
repres
step
toward
erad
drugresist
bacteri
infect
similar
approach
engin
phage
describ
chri
voigt
group
pioneer
design
environment
control
bacteria
invad
cancer
cell
deliv
cytotox
agent
e
coli
engin
target
human
cancer
cell
line
deriv
cervic
hela
hepatocellular
hep
carcinoma
select
invas
solid
tumor
author
construct
hypoxiainduc
express
vector
gener
solid
tumor
display
lowoxygen
environ
author
use
invasin
gene
yersinia
pseudotuberculosi
clone
control
hypoxiaregul
formatedehydrogenas
promot
p
fdhf
e
coli
harbor
construct
select
invad
cell
lowoxygen
condit
result
pave
way
futur
anticanc
studi
anim
select
target
tumor
spare
healthi
tissu
could
potenti
improv
use
synthet
network
recent
develop
guid
bacteria
desir
locat
gradient
small
molecul
e
coli
phosphatas
chez
trigger
dephosphoryl
chey
turn
make
e
coli
run
tumbl
phosphoryl
chey
induc
tumbl
control
chemotaxi
chez
gene
fuse
theophyllinerespons
aptam
result
theophyllineinduc
chez
express
could
shown
engin
e
coli
follow
theophyllin
gradient
open
possibl
engin
bacteria
follow
gradient
patholog
messeng
eg
tumor
marker
invad
kill
malign
cell
treat
diseas
good
prevent
happen
even
better
recent
studi
luke
alphey
group
describ
strategi
control
insect
serv
host
human
pathogen
like
plasmodium
falciparum
caus
agent
malaria
aim
erad
specif
insect
popul
group
develop
synthet
gene
switch
confer
induc
femalespecif
domin
lethal
mediterranean
fruit
fli
cerat
capitata
agricultur
pest
approach
male
fli
harbor
engin
transgen
would
releas
environ
would
mate
wildtyp
femal
therebi
compet
wildtyp
male
wildtyp
femal
femal
progeni
expect
die
compromis
reproduct
insect
pest
enabl
effici
breed
engin
fli
femalespecif
lethal
must
suppress
breed
phase
therefor
author
disrupt
insect
codonusag
adapt
variant
tetracyclinerespons
repressor
ttav
intron
exclus
splice
femal
organ
yield
translationcompet
ttav
fig
intronencod
ttav
place
control
ttavinduc
promot
result
posit
feedback
loop
trigger
high
level
ttav
femal
toxic
development
phase
probabl
transcript
squelch
effect
transactiv
domain
contain
ttav
result
kill
femal
progeni
presenc
tetracyclin
insect
food
ttavamplifi
posit
feedback
loop
interrupt
yield
femal
progeni
breed
purpos
owe
conserv
sexdepend
splice
mechan
author
suggest
procedur
might
gener
use
control
mosquitotransmit
malaria
fact
unit
state
depart
agricultur
decid
may
includ
use
genet
engin
insect
agenc
futur
plant
pest
control
program
approach
consid
minim
potenti
impact
human
health
nontarget
speci
environment
qualiti
compar
tradit
chemicalbas
insect
control
strategi
discoveri
drug
provid
basi
treat
diseas
manufactur
drug
substanc
econom
largescal
manner
affect
whether
drug
avail
peopl
outsid
rich
industri
countri
small
molecul
address
classic
synthet
chemistri
onethird
market
smallmolecul
therapeut
drug
deriv
natur
product
isol
natur
host
product
therapeut
streptomyc
fungi
eg
antibiot
done
costeffect
largescal
product
plant
secondari
metabolit
pose
enorm
econom
challeng
exampl
antimalaria
drug
artemisinin
sesquiterpen
lacton
endoperoxid
extract
sweet
wormwood
artemisia
annua
l
short
suppli
unafford
malaria
patient
anoth
exampl
taxol
highli
decor
diterpenoid
deriv
pacif
yew
tree
taxu
brevifolia
nutt
high
chemotherapeut
valu
lung
ovarian
breast
cancer
taxol
precursor
current
produc
plant
cell
cultur
transform
taxol
chemic
synthesi
costli
process
given
low
yield
plant
cell
cultur
design
costeffect
manufactur
process
therapeut
compound
difficult
produc
synthet
biologist
work
assembl
complet
biosynthesi
pathway
e
coli
saccharomyc
cerevisia
complex
endeavor
express
level
biosynthet
enzym
must
orchestr
result
streamlin
biosynthesi
avoid
toxic
accumul
deplet
intermedi
substanc
semin
effort
jay
keasl
group
engin
e
coli
produc
artemisin
acid
substanc
readili
convert
artemisinin
organ
chemistri
product
artemisin
acid
requir
enzymat
reaction
start
acetylcoa
mevalon
farnesyl
pyrophosph
amorphadien
key
intermedi
fig
follow
work
illustr
gener
engin
strategi
optim
design
biosynthesi
pathway
increas
yield
split
overal
biosynthesi
operon
suboperon
eg
one
catalyz
acetylcoa
mevalon
one
transform
mevalon
farnesyl
pyrophosph
enabl
independ
construct
valid
optim
operon
ii
shown
similar
pathway
differ
host
differ
efficaci
exampl
shown
yeast
mevalon
pathway
transfer
e
coli
result
substanti
higher
amorphadien
concentr
use
nativ
dxp
pathway
e
coli
iii
avoid
accumul
intermedi
metabolit
toxic
concentr
eg
direct
mevalon
precursor
hmgcoa
addit
copi
next
downstream
enzym
incorpor
eg
hmgcoa
reductas
therebi
increas
overal
yield
iv
optim
balanc
express
level
three
biosynthet
gene
determin
convers
acetylcoa
mevalon
librari
tunabl
intergen
region
tigr
construct
contain
control
element
construct
genet
femalespecif
insect
lethal
circuit
insect
codon
usageoptim
tetracyclinerespons
transactiv
ttav
engin
control
heat
shock
minim
promot
p
min
fuse
repeat
ttavspecif
oper
teto
sexspecif
intron
insert
ttav
yield
fulllength
ttav
translat
product
follow
correct
splice
femal
insect
result
ttav
protein
activ
p
min
posit
feedback
loop
result
high
ttav
protein
level
exhibit
lethal
effect
whole
organ
probabl
due
transcript
squelch
femalespecif
lethal
posit
feedback
loop
interrupt
tetracyclin
tet
therebi
enabl
propag
femal
insect
breed
purpos
presenc
antibiot
includ
mrna
secondari
structur
rnase
cleavag
site
rb
sequest
sequenc
tigr
element
clone
intergen
region
mevalon
pathway
screen
high
mevalon
product
result
product
increas
sevenfold
compar
nonoptim
operon
v
heterolog
enzym
sometim
difficult
express
e
coli
potenti
limit
overal
biosynthet
capac
microbi
system
exampl
highlevel
express
cytochrom
amorphadien
monooxygenas
requir
codon
optim
insert
heterolog
transmembran
domain
well
coexpress
redox
partner
fouryear
concentr
effort
combin
abovement
strategi
result
fold
increas
product
level
intermedi
substanc
amorphadien
final
product
yield
mgl
artemisin
acid
readili
convert
activ
artemisinin
organ
chemistri
similar
approach
jay
keasl
group
engin
artemisin
acid
biosynthesi
pathway
cerevisia
result
product
gl
artemisin
acid
optim
bioprocess
work
optim
artemisinin
product
advanc
demonstr
synthet
biolog
make
possibl
produc
difficult
natur
compound
overcom
shortag
suppli
natur
therapeut
emerg
synthet
biolog
character
design
synthet
gene
network
show
complex
dynam
behavior
well
provid
tool
ration
construct
cell
desir
featur
design
network
current
consid
nextgener
geneand
cellbas
therapi
well
level
drug
discoveri
process
develop
known
second
wave
synthet
biolog
product
artemisinin
paradigm
synthet
biolog
impact
drug
develop
manufactur
synthet
biologybas
product
process
antimalaria
compound
expect
enter
market
support
allianc
institut
oneworld
health
amyri
biotechnolog
sanofi
aventi
also
use
genet
engin
insect
recent
valid
open
field
trial
obtain
posit
evalu
unit
state
depart
synthet
metabol
pathway
e
coli
product
artemisin
acid
four
express
unit
confer
enzymat
step
requir
produc
artemisin
acid
start
acetylcoa
upstream
mevalon
pathway
import
cerevisia
acetylcoa
molecul
convert
mevalon
mevalon
process
farnesyl
pyrophosph
downstream
part
import
mevalon
pathway
farnesyl
pyrophosph
circular
amorphadien
synthas
oxid
artemisin
acid
ntermin
engin
codonoptim
cytochrom
monooxygenas
deriv
artemisia
annua
artemisin
acid
convert
pharmaceut
activ
substanc
artemisinin
chemic
reduct
peroxid
oxid
ring
closur
wwwdrugdiscoverytodaycom
agricultur
clinic
valid
synthet
biologybas
biopharmaceut
engin
phage
cancerinvad
bacteria
immin
probabl
success
wildtyp
phage
alreadi
use
treat
bacteri
infect
treatment
cancer
patient
attenu
salmonella
promis
rapid
develop
synthet
biolog
exemplifi
identif
definit
character
biolog
part
elabor
computerbas
model
design
principl
well
advanc
genom
synthesi
technolog
revolution
entir
drug
discoveri
process
assembl
design
network
reconstruct
synthet
signal
pathway
lead
identif
novel
target
develop
tailor
drug
howev
synthet
biolog
impact
clinic
applic
beyond
drug
discoveri
compon
synthet
design
circuit
recent
adapt
construct
stimulisens
biomateri
releas
embed
therapeut
growth
factor
respons
smallmolecul
drug
recent
achiev
medic
relat
translat
synthet
biolog
describ
provid
inkl
synthet
biolog
pois
becom
groundbreak
tool
drug
design
discoveri
process
help
facilit
discoveri
product
novel
therapeut
prevent
strategi
address
unmet
medic
need
